中日知识产权融资制度的比较分析——基于创新药物专利质押融资现状的案例研究

Comparing the Intellectual Property Financing Policies between China and Japan:A Case Study of Innovative Drugs' Patent-Pledging

作为一种现代融资工具,知识产权融资已成为创新药物研发的主要融资渠道。日本是最早开展知识产权融资业务的国家,其药品专利质押贷款是推动日本医药科技创新的源动力。中日两国在融资额度、融资期限、融资企业数方面均存在较大差异,而导致这种差异的原因则是两国融资制度的不同。我国应借鉴日本知识产权融资政策的经验,加快我国知识产权评估体系以及信用担保体系的建设,为创新药物研发提供良好的融资环境。

Intellectual property （R＆D） of innovative drugs. J Pledging of drug patents has be financing has played an increasingly vital role in the research and development apan is the earliest pioneer in the business of intellectual property financing. en the motive power for the innovation of the Japanese pharmaceutical industry A comparison of China and Japan reveals reveals important bers of financing. These differences rise from the country China can learn from the Japanese experiences to provide differences in the amounts, periods and case num- -specific intellectual property financing policies a favorable environment for intellectual property fi- nancing of innovative drugs, by means of the development of the intellectual property evaluation system and the credit guarantee system